TCR2 Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 09/01/22
TCR² Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/08/22
TCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial OfficerGlobeNewsWire • 06/27/22
TCR² Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/12/22
TCR² Therapeutics Reports Fourth Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/22/22
TCR² Therapeutics to Highlight Off-the-Shelf TRuC-T Cell at the American Association of Cancer Research Annual Meeting 2022GlobeNewsWire • 03/08/22
Here's Why TCR2 Therapeutics Inc. (TCRR) is Poised for a Turnaround After Losing 20.2% in 4 WeeksZacks Investment Research • 01/13/22
TCR² Therapeutics Announces Experienced Biotech Executive Rosemary Harrison as Chief Business and Strategy OfficerGlobeNewsWire • 01/12/22
TCR² Therapeutics Announces 2022 Strategic Priorities and Anticipated MilestonesGlobeNewsWire • 01/10/22
TCR² Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/10/21
TCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid TumorsGlobeNewsWire • 10/25/21
TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid TumorsGlobeNewsWire • 09/17/21
TCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in Mesothelin-Expressing Solid TumorsGlobeNewsWire • 09/13/21
TCR² Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 09/07/21
TCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of CholangiocarcinomaGlobeNewsWire • 09/02/21
TCR² Therapeutics Announces Renowned Translational Medicine Leader Priti Hegde Joins Its Board of DirectorsGlobeNewsWire • 08/26/21